Matthieu Rouffet

Matthieu Rouffet

  • Assistant Professor
  • Phone: 619.849.3278

Education

  • Ph.D., Medicinal Chemistry, School of Pharmacy of Reims, France
  • M.S., Organic Chemistry, University of Reims, France
  • B.S., Chemistry, University of Reims, France

Background

Education:

 

  

2008

Ph.D., Medicinal Chemistry, School of Pharmacy of Reims, France

 

2005

M.S., Organic Chemistry, University of Reims, France

 

2000-2004

B.S., Chemistry, University of Reims, France

Dissertation:

  

 

Synthesis, biological evaluation and determination of the mode of binding of sulfonylhydrazides as MMP inhibitors
Advisor: Pr. Dominique Guillaume

Experience:

  

2009-2011

Post-Doctoral Associate, University of California, San Diego, California

 

2005-2008

Graduate Researcher, School of Pharmacy, Reims, France

 

2004

Undergraduate Researcher, University of York, UK

Research

Dr. Rouffet’s research focuses on the development of novel anthrax lethal factor inhibitors. Anthrax has been well documented several years ago as it was used for bioterrorism after the attacks of 9/11. Currently, the vaccines against anthrax suffer a lot of adverse reactions and so another approach to its inhibition is required. Dr. Rouffet’s current research will focus on the development of new molecules that can bind the zinc ion to a specific metalloenzyme found in anthrax. 

Publications

  1. Rouffet, M. and Cohen, S. M., “Emerging trends in metalloprotein inhibition”, Dalton Trans., 2011, 40, 3445.
  2.  Martin, D. P.; Rouffet, M.; and Cohen, S. M., “Illuminating Metal Ion sensors- Benzimidazolesulfonamide metal complexes”, Inorg. Chem., 2010, 49, 22, 10226–10228
  3. Rouffet, M.; De Oliveira, C. A. F.; Udi, Y.; Agrawal A.; Sagi, I.; McCammon, J. A. and Cohen, S.M., “From Sensors to Silencers: Quinoline- and Benzimidazole-Sulfonamides as Inhibitors for Zinc Proteases”, J. Am. Chem. Soc., 2010, 132, 8232–8233
  4. Rouffet, M. ; Denhez, C.; Bourguet, E.; Bohr, F. and Guillaume, D., In silico study of MMP inhibition, Org. Biomol. Res., 2009, 7, 18, 3817-3825
  5. LeDour, G.; Moroy, G.; Rouffet, M.; Bourguet. E.; Guillaume, D.; Decarme, M.; ElMourabit, H.; Augé, F.; Alix, A.J.P.; Laronze, J.Y.; Bellon, G.; Hornebeck, W. and  Sapi, J., “Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity”, Bioorg. Med. Chem., 2008, 16, 8745–8759